Aptose Biosciences Inc. (APTOF): Nasdaq/NYSE listing notice — Aptose receives Nasdaq deficiency notice for stockholders' equity below $2.5M

Aptose Biosciences Inc.

Nasdaq notified Aptose that stockholders' equity as of Dec 31, 2023 was below the $2.5M minimum.
Company believes subsequent financings on Jan 30-31, 2024 bring equity above the threshold.
Must submit a compliance plan by May 17, 2024; if accepted, extension up to 180 days from April 2, 2024.
Alternative listing standards not met: market value below $35M and net income below $500K in last fiscal year.
Failure could lead to delisting hearing; no immediate effect on Nasdaq Capital Market listing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 2, 2024, Aptose Biosciences Inc. (the “Company”) received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company as of December 31, 2023, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2024, was below the minimum requirement of $2,500,000. Notwithstanding the Notification Letter, the Company believes that following the closing of its financings on January 30, 2024 and January 31, 2024

View on SEC.gov

Browse all listing & compliance notices →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.